Columbia University

Technology Ventures


Proterris: Proterris is a P2/3 clinical-stage firm that has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide. CO’s therapeutic rationale has been supported by more than 50 preclinical studies and several clinical trials, including those supported with ~$32 million in NIH and DoD funding to date. The therapeutic indications addressable by both inhaled CO (iCO) and CO-releasing molecules (CORMs) cover a wide range of fibrotic, transplantation, other ischemia-reperfusion injury, oncology and anti-inflammatory disorders. Proterris has prioritized CO development in kidney and lung transplant, immuno-oncology and non-alcoholic steatohepatitis (NASH), with significant opportunities in a number of other indications, including but not limited to acute kidney injury (AKI), renal fibrosis, and idiopathic pulmonary fibrosis (IPF).

To learn more about this opportunity, contact:

Sara Gusik
Senior Technology Licensing Officer